BR112014002363A2 - agonistas do domínio de homologia src 2 contendo proteína tirosina fosfatase - 1 e métodos de tratamento utilizando os mesmos - Google Patents
agonistas do domínio de homologia src 2 contendo proteína tirosina fosfatase - 1 e métodos de tratamento utilizando os mesmosInfo
- Publication number
- BR112014002363A2 BR112014002363A2 BR112014002363-8A BR112014002363A BR112014002363A2 BR 112014002363 A2 BR112014002363 A2 BR 112014002363A2 BR 112014002363 A BR112014002363 A BR 112014002363A BR 112014002363 A2 BR112014002363 A2 BR 112014002363A2
- Authority
- BR
- Brazil
- Prior art keywords
- src
- same
- treatment methods
- protein tyrosine
- containing protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
- A01N31/08—Oxygen or sulfur directly attached to an aromatic ring system
- A01N31/14—Ethers
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/16—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds containing nitrogen-to-oxygen bonds
- A01N33/18—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pest Control & Pesticides (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161514555P | 2011-08-03 | 2011-08-03 | |
US61/514,555 | 2011-08-03 | ||
PCT/US2012/049446 WO2013020014A1 (en) | 2011-08-03 | 2012-08-03 | Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014002363A2 true BR112014002363A2 (pt) | 2017-06-13 |
Family
ID=47629697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014002363-8A BR112014002363A2 (pt) | 2011-08-03 | 2012-08-03 | agonistas do domínio de homologia src 2 contendo proteína tirosina fosfatase - 1 e métodos de tratamento utilizando os mesmos |
Country Status (18)
Country | Link |
---|---|
US (1) | US9216950B2 (pt) |
EP (1) | EP2739139B1 (pt) |
JP (1) | JP2014527043A (pt) |
KR (1) | KR101661825B1 (pt) |
CN (1) | CN104010501B (pt) |
AU (1) | AU2012289961C1 (pt) |
BR (1) | BR112014002363A2 (pt) |
CA (1) | CA2843330C (pt) |
ES (1) | ES2762193T3 (pt) |
IL (1) | IL230601A (pt) |
IN (1) | IN2014MN00125A (pt) |
MX (1) | MX353205B (pt) |
MY (1) | MY175797A (pt) |
PL (1) | PL2739139T3 (pt) |
RU (1) | RU2584986C2 (pt) |
TW (1) | TWI507191B (pt) |
WO (1) | WO2013020014A1 (pt) |
ZA (1) | ZA201400757B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014032755A2 (en) * | 2012-08-29 | 2014-03-06 | Merck Patent Gmbh | Ddr2 inhibitors for the treatment of osteoarthritis |
JP6489658B2 (ja) * | 2013-04-25 | 2019-03-27 | シービーエス バイオサイエンス,カンパニー,リミテッド | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 |
WO2015051149A1 (en) * | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
CA2992024A1 (en) * | 2015-08-31 | 2017-03-09 | Toray Industries, Inc. | Urea derivative and use therefor |
EP3345894B1 (en) * | 2015-09-02 | 2021-12-29 | Chen, Kuenfeng | Compound having protein tyrosine phosphatase shp-1 agonist activity |
EP3500257A4 (en) * | 2016-08-17 | 2020-01-22 | Icahn School of Medicine at Mount Sinai | KINASE INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER |
WO2018054354A1 (zh) * | 2016-09-22 | 2018-03-29 | 陈昆锋 | 含有src同源区2的蛋白酪氨酸磷酸酶-1激动剂用于改善纤维化的用途 |
SG11201906671SA (en) * | 2017-02-03 | 2019-08-27 | Univ California | Compositions and methods for inhibiting reticulon 4 |
JP7546549B2 (ja) | 2018-09-10 | 2024-09-06 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
CN113402456B (zh) * | 2020-03-16 | 2023-03-03 | 深圳大学 | 一种抗肿瘤药物以及一种化合物或其药学上可接受的盐在抗肿瘤药物中的应用 |
CN112084184B (zh) * | 2020-09-15 | 2022-12-16 | 青海省地质测绘地理信息院 | 一种在不同gis平台之间异构数据属性传递的方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1241832B (de) * | 1963-02-23 | 1967-06-08 | Hoechst Ag | Verfahren zur Herstellung von Pyrimidiniumverbindungen |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
WO1993015043A1 (en) * | 1992-01-24 | 1993-08-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Arylalkananilide compound and pharmaceutical use thereof |
ATE174593T1 (de) * | 1993-04-30 | 1999-01-15 | Yamanouchi Pharma Co Ltd | Neue bisoxadiazolidinderivate |
TR200002616T2 (tr) * | 1997-12-22 | 2000-11-21 | Bayer Corporation | Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CZ2002487A3 (cs) * | 1999-08-20 | 2002-06-12 | Dow Agrosciences Llc | Fungicidní heterocyklické aromatické amidy, prostředky na jejich bázi, způsoby jejich pouľití a přípravy |
DE19954312A1 (de) * | 1999-11-11 | 2001-05-17 | Bayer Ag | Substituierte Phenyluracile |
JP4529119B2 (ja) * | 2001-08-09 | 2010-08-25 | 小野薬品工業株式会社 | カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤 |
CN101027283A (zh) * | 2004-04-26 | 2007-08-29 | 阿斯利康(瑞典)有限公司 | 用作血管破坏剂的3,4-二取代马来酰亚胺 |
SE0401969D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
WO2006091450A1 (en) * | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
US9029401B2 (en) | 2011-02-14 | 2015-05-12 | The Regents Of The University Of California | Sorafenib derivatives as sEH inhibitors |
-
2012
- 2012-08-03 CN CN201280038359.7A patent/CN104010501B/zh active Active
- 2012-08-03 AU AU2012289961A patent/AU2012289961C1/en active Active
- 2012-08-03 PL PL12819260T patent/PL2739139T3/pl unknown
- 2012-08-03 US US14/235,620 patent/US9216950B2/en active Active
- 2012-08-03 BR BR112014002363-8A patent/BR112014002363A2/pt not_active IP Right Cessation
- 2012-08-03 WO PCT/US2012/049446 patent/WO2013020014A1/en active Application Filing
- 2012-08-03 CA CA2843330A patent/CA2843330C/en active Active
- 2012-08-03 MY MYPI2014700189A patent/MY175797A/en unknown
- 2012-08-03 RU RU2014101953/04A patent/RU2584986C2/ru active
- 2012-08-03 JP JP2014523113A patent/JP2014527043A/ja active Pending
- 2012-08-03 ES ES12819260T patent/ES2762193T3/es active Active
- 2012-08-03 KR KR1020147003923A patent/KR101661825B1/ko active IP Right Grant
- 2012-08-03 TW TW101128133A patent/TWI507191B/zh active
- 2012-08-03 IN IN125MUN2014 patent/IN2014MN00125A/en unknown
- 2012-08-03 EP EP12819260.6A patent/EP2739139B1/en active Active
- 2012-08-03 MX MX2014001157A patent/MX353205B/es active IP Right Grant
-
2014
- 2014-01-22 IL IL230601A patent/IL230601A/en active IP Right Grant
- 2014-01-31 ZA ZA2014/00757A patent/ZA201400757B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI507191B (zh) | 2015-11-11 |
EP2739139A1 (en) | 2014-06-11 |
ZA201400757B (en) | 2015-10-28 |
AU2012289961B2 (en) | 2016-05-19 |
ES2762193T3 (es) | 2020-05-22 |
JP2014527043A (ja) | 2014-10-09 |
EP2739139A4 (en) | 2015-06-10 |
KR20140039331A (ko) | 2014-04-01 |
IL230601A0 (en) | 2014-03-31 |
CA2843330C (en) | 2016-09-20 |
TW201320997A (zh) | 2013-06-01 |
WO2013020014A1 (en) | 2013-02-07 |
EP2739139B1 (en) | 2019-09-25 |
CN104010501A (zh) | 2014-08-27 |
US20140200239A1 (en) | 2014-07-17 |
AU2012289961C1 (en) | 2016-09-01 |
RU2014101953A (ru) | 2015-09-10 |
MY175797A (en) | 2020-07-09 |
NZ620434A (en) | 2015-08-28 |
MX353205B (es) | 2018-01-08 |
IN2014MN00125A (pt) | 2015-06-12 |
IL230601A (en) | 2017-07-31 |
AU2012289961A1 (en) | 2014-02-20 |
US9216950B2 (en) | 2015-12-22 |
CA2843330A1 (en) | 2013-02-07 |
PL2739139T3 (pl) | 2020-06-15 |
CN104010501B (zh) | 2016-05-04 |
MX2014001157A (es) | 2015-02-04 |
RU2584986C2 (ru) | 2016-05-27 |
KR101661825B1 (ko) | 2016-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014002363A2 (pt) | agonistas do domínio de homologia src 2 contendo proteína tirosina fosfatase - 1 e métodos de tratamento utilizando os mesmos | |
LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
IL245042A0 (en) | Treatment with proton tyrosine kinase inhibitors and immunotherapy | |
HK1221953A1 (zh) | 酪氨酸蛋白激酶調節劑及其應用方法 | |
SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
BR112014019825A2 (pt) | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos | |
DK3010506T3 (da) | Pridopidin i behandling af huntingtons sygdom | |
EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201590402A1 (ru) | ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201270722A1 (ru) | Формы рифаксимина и их применение | |
EP3464638A4 (en) | USE OF BIOMARKERS TO DETERMINE SENSITIVITY TO TREATMENT OF A DISEASE | |
EA201500172A1 (ru) | Модифицированные полипептиды фактора х и их применение | |
BR112015001712A2 (pt) | uso de s-pindolol para o tratamento da caquexia e sarcopenia | |
EA201390254A1 (ru) | Модифицированные полипептиды релаксина и их применение | |
EA201401065A1 (ru) | Ang2-связывающие молекулы | |
CO6940375A2 (es) | Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo | |
DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
BR112015003032A2 (pt) | anticorpos anti-jagged e métodos de utilização'. | |
HK1260897A1 (zh) | 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法 | |
BR112014009456A2 (pt) | uso de melatonina para o tratamento e/ou prevenção de mucosite | |
CL2015000537A1 (es) | Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos. | |
FR3007287B1 (fr) | Composition comprenant l'association d'un polymere acrylique et d'une silicone aminee | |
FR2993564B1 (fr) | Derives d'imidazopyridine utiles dans le traitement du diabete | |
BR112015006272A2 (pt) | ''uso cosmético, composto, composição cosmética e método de tratamento cosmético'' |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |